Lonza’s Synaffix and Sidewinder Therapeutics announce multi-target License agreement to advance development of nextgeneration Bispecific ADCs

CAR-T Digest - August 2020

Weekly Digest - January 2026

7 January 2026: Lonza’s Synaffix and Sidewinder Therapeutics announce multi-target License agreement to advance development of next generation Bispecific ADCs

Lonza (through its subsidiary Synaffix) and Sidewinder Therapeutics entered a multi-target licensing agreement to develop first-in-class bispecific ADCs for solid tumors
The agreement gives Sidewinder access to Lonza’s clinically validated, site-specific ADC platform, including GlycoConnect® conjugation, HydraSpace® polar spacer technology, and the toxSYN® linker-payload system
By combining Sidewinder’s bispecific antibody pipeline with Synaffix’s ADC technologies, the collaboration aims to enhance tumor-cell specificity, internalization, and therapeutic index while minimizing off-target toxicity
Lonza is eligible to receive upfront payments, development, regulatory, and commercial milestones, as well as royalties on net sales, while manufacturing proprietary technology components; Sidewinder will lead research, development, manufacturing, and commercialization
Sidewinder plans to initiate a clinical trial for a first-in-class bispecific ADC in 2026, marking a key step toward advancing next-generation precision ADC therapies for cancer patients